Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
Journal of virology    August 13, 2014   Volume 88, Issue 20 12077-12086 doi: 10.1128/JVI.01406-14
Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J.Alphavirus replicons were evaluated as potential vaccine candidates for Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), or eastern equine encephalitis virus (EEEV) when given individually or in combination (V/W/E) to mice or cynomolgus macaques. Individual replicon vaccines or the combination V/W/E replicon vaccine elicited strong neutralizing antibodies in mice to their respective alphavirus. Protection from either subcutaneous or aerosol challenge with VEEV, WEEV, or EEEV was demonstrated out to 12 months after vaccination in mice. Individual replicon v...
Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.
Veterinary research    August 9, 2014   Volume 45, Issue 1 82 doi: 10.1186/s13567-014-0082-y
Ma J, Wang SS, Lin YZ, Liu HF, Liu Q, Wei HM, Wang XF, Wang YH, Du C, Kong XG, Zhou JH, Wang X.The Chinese attenuated equine infectious anemia virus (EIAV) vaccine has successfully protected millions of equine animals from EIA disease in China. Given that the induction of immune protection results from the interactions between viruses and hosts, a better understanding of the characteristics of vaccine strain infection and host responses would be useful for elucidating the mechanism of the induction of immune protection by the Chinese attenuated EIAV strain. In this study, we demonstrate in equine monocyte-derived macrophages (eMDM) that EIAVFDDV13, a Chinese attenuated EIAV strain, indu...
Focus on: vaccination against equine grass sickness.
The Veterinary record    August 2, 2014   Volume 175, Issue 5 114-115 doi: 10.1136/vr.g4684
Ireland J.Jo Ireland of the Animal Health Trust describes a new field trial of a potential vaccine against equine grass sickness.
Efficacy of a Parapoxvirus ovis-based immunomodulator against equine herpesvirus type 1 and Streptococcus equi equi infections in horses.
Veterinary microbiology    July 27, 2014   Volume 173, Issue 3-4 232-240 doi: 10.1016/j.vetmic.2014.07.015
Ons E, Van Brussel L, Lane S, King V, Cullinane A, Kenna R, Lyons P, Hammond TA, Salt J, Raue R.The efficacy of Zylexis®, an immunomodulator in horses based on inactivated Parapoxvirus ovis (iPPVO), was assessed using an equine herpesvirus type 1 (EHV-1) challenge model in the presence of a natural infection with Streptococcus equi equi (S. equi). Eleven horses were treated with iPPVO and twelve were kept as controls. Six horses were challenged with EHV-1 and commingled with the horses on study. Animals were dosed on Days -2, 0 (just before commingling) and Day 7. On Day 11 significantly less nasal discharge, enlarged lymph nodes, EHV-1 shedding and lower rectal temperatures were observ...
CpG-ODN class C-mediated immunostimulation and its potential against Trypanosoma evansi in equines.
International immunopharmacology    July 24, 2014   Volume 22, Issue 2 366-370 doi: 10.1016/j.intimp.2014.07.016
Manuja A, Kumar P, Kumar R, Kumar B, Singha H, Sharma RK, Yadav SC.Trypanosoma evansi is the causative agent of surra, which is the most common and widespread trypansomal disease. The infection is mainly restricted to animals, but it has also been documented in human. Trypanosomes possess the thick immunogenic surface coat known as variant surface glycoprotein (VSG). The parasite modifies the VSG constantly resulting in continuous antigenic variations and thus evades the host immune response. Due to antigenic variations, vaccination against trypanosomosis is not useful. Therefore, alternate strategies to augment the immune response are required. CpG-ODN class...
Structural and antigenic features of the synthetic SF23 peptide corresponding to the receptor binding fragment of diphtheria toxin.
Molecular immunology    July 23, 2014   Volume 63, Issue 2 235-244 doi: 10.1016/j.molimm.2014.07.008
Khrustaleva TA, Khrustalev VV, Barkovsky EV, Kolodkina VL, Astapov AA.The SF23 peptide corresponding to the receptor binding fragment of diphtheria toxin (residues 508-530) has been synthesized. This fragment forming a protruding beta hairpin has been chosen because it is the less mutable B-cell epitope. Affine chromatography and ELISA show that antibodies from the sera of persons infected by toxigenic Corynebacterium diphtheriae and those immunized by diphtheria toxoid are able to bind the synthetic SF23 peptide. There are antibodies recognizing the SF23 peptide in the serum of horses hyperimmunized with diphtheria toxoid. Analysis of circular dichroism spectra...
Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.
Vaccine    July 18, 2014   Volume 32, Issue 39 4932-4937 doi: 10.1016/j.vaccine.2014.07.031
Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P.African horse sickness (AHS) is an equine disease with a mortality of up to 90% for susceptible horses. The causative agent AHS virus (AHSV) is transmitted by species of Culicoides. AHSV serogroup within the genus Orbivirus of the Reoviridae family consists of nine serotypes that show no or very limited cross-neutralization. Of the seven structural proteins (VP1-VP7) of AHSV, VP2 is the serotype specific protein, and the major target for neutralizing antibodies. In this report, recombinant VP2 proteins of all nine serotypes were expressed individually by the baculovirus expression system and t...
A brief introduction to equine influenza and equine influenza viruses.
Methods in molecular biology (Clifton, N.J.)    June 6, 2014   Volume 1161 365-370 doi: 10.1007/978-1-4939-0758-8_31
Chambers TM.Equine influenza virus (EIV) is a common respiratory pathogen of horses and other equids in most parts of the world. EIV are Type A influenza viruses and two subtypes are known: H3N8 and H7N7. Both are believed to have evolved from avian influenza virus ancestors. The H3N8 subtype circulates widely, but the H7N7 subtype is thought to be extinct. The clinical disease in horses, caused by either subtype, is an upper respiratory infection of varying severity depending upon the immune status of the individual animal. It is not normally life-threatening in itself except in very young foals; however...
The potential impact of a single amino-acid substitution on the efficacy of equine influenza vaccines.
Equine veterinary journal    June 3, 2014   Volume 47, Issue 4 456-462 doi: 10.1111/evj.12290
Yamanaka T, Cullinane A, Gildea S, Bannai H, Nemoto M, Tsujimura K, Kondo T, Matsumura T.The protection induced by an equine influenza (EI) vaccine strain depends on its antigenic relatedness to the challenge virus. Although the World Organisation for Animal Health (OIE) recommend that both Florida sublineage clade 1 (Fc1) and clade 2 (Fc2) viruses should be included in EI vaccines, Japanese EI vaccines have not, thus far, been updated to include a Fc2 virus. Objective: To evaluate the efficacy of antibodies raised against Japanese EI vaccine strains in the neutralisation of recent Fc2 viruses. Methods: Antigenic analysis. Methods: Virus neutralisation tests were performed using a...
Innovative immunization protocols using chimeric recombinant protein for the production of polyspecific loxoscelic antivenom in horses.
Toxicon : official journal of the International Society on Toxinology    May 28, 2014   Volume 86 59-67 doi: 10.1016/j.toxicon.2014.05.007
Figueiredo LF, Dias-Lopes C, Alvarenga LM, Mendes TM, Machado-de-Ávila RA, McCormack J, Minozzo JC, Kalapothakis E, Chávez-Olórtegui C.A chimeric protein (rCpLi) was constructed expressing three epitopes of rLiD1, a dermonecrotic toxin from the venom of Loxosceles intermedia spider. We have analyzed the neutralization potential of sera obtained by immunization of horses with rCpLi and rCpLi combined with initial doses of venoms and compared these with antivenom traditionally produced in horses using crude Loxosceles gaucho, Loxosceles laeta and L. intermedia venoms as antigens. We have demonstrated by ELISA that horses immunized with three initial doses of crude venom containing mixtures of L. intermedia, L. gaucho and L. lae...
Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.
Vaccines    May 27, 2014   Volume 2, Issue 2 397-421 doi: 10.3390/vaccines2020397
Schwartz EJ, Smith RJ.The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV ...
Immediate-early protein of equid herpesvirus type 1 as a target for cytotoxic T-lymphocytes in the Thoroughbred horse.
The Journal of general virology    May 16, 2014   Volume 95, Issue Pt 8 1783-1789 doi: 10.1099/vir.0.065888-0
Kydd JH, Case R, Minke J, Audonnet JC, Wagner B, Antczak DF.Cytotoxic T-lymphocytes (CTLs) are associated with protective immunity against disease caused by equid herpesvirus type 1 (EHV-1). However, the EHV-1 target proteins for CTLs are poorly defined. This limits the development of vaccine candidates designed to stimulate strong CTL immunity. Here, classical CTL assays using lymphocytes from horses of three defined MHC class I types that experienced natural infection with EHV-1 and a modified vaccinia virus construct containing an EHV-1 gene encoding the immediate-early (IE) protein are reported. Horses homozygous for the equine leukocyte antigen (E...
Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
Vaccine    May 14, 2014   Volume 32, Issue 29 3670-3674 doi: 10.1016/j.vaccine.2014.04.036
Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J.African horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species of equidae and causes high mortality in horses. Previously, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 was shown to induce virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR -/-) against virulent AHSV challenge. This study builds on the previous work, examining the protective efficacy of MVA-VP2 vaccination in the natural host of AHSV infection. A study group of 4 horses was vaccinated twice wit...
Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
Vaccine    May 9, 2014   Volume 32, Issue 29 3611-3616 doi: 10.1016/j.vaccine.2014.04.087
Crafford JE, Lourens CW, Smit TK, Gardner IA, MacLachlan NJ, Guthrie AJ.African horse sickness (AHS) is typically a highly fatal disease in susceptible horses and vaccination is currently used to prevent the occurrence of disease in endemic areas. Similarly, vaccination has been central to the control of incursions of African horse sickness virus (AHSV) into previously unaffected areas and will likely play a significant role in any future incursions. Horses in the AHSV-infected area in South Africa are vaccinated annually with a live-attenuated (modified-live virus [MLV]) vaccine, which includes a cocktail of serotypes 1, 3, 4 (bottle 1) and 2, 6-8 (bottle 2) deli...
Efficacy of a non-updated, Matrix-C-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge.
The Veterinary record    May 2, 2014   Volume 174, Issue 25 633 doi: 10.1136/vr.101993
Pouwels HG, Van de Zande SM, Horspool LJ, Hoeijmakers MJ.Assessing the ability of current equine influenza vaccines to provide cross-protection against emerging strains is important. Horses not vaccinated previously and seronegative for equine influenza based on haemagglutination inhibition (HI) assay were assigned at random to vaccinated (n=7) or non-vaccinated (control, n=5) groups. Vaccination was performed twice four weeks apart with a 1 ml influenza subunit (A/eq/Prague/1/56, A/eq/Newmarket/1/93, A/eq/Newmarket/2/93), tetanus toxoid vaccine with Matrix-C adjuvant (EquilisPrequenza Te). All the horses were challenged individually by aerosol wi...
Mouse lung infection model to assess Rhodococcus equi virulence and vaccine protection.
Veterinary microbiology    March 30, 2014   Volume 172, Issue 1-2 256-264 doi: 10.1016/j.vetmic.2014.03.026
González-Iglesias P, Scortti M, MacArthur I, Hapeshi A, Rodriguez H, Prescott JF, Vazquez-Boland JA.The pathogenic actinomycete Rhodococcus equi causes severe purulent lung infections in foals and immunocompromised people. Although relatively unsusceptible to R. equi, mice are widely used for in vivo studies with this pathogen. The most commonly employed mouse model is based on systemic (intravenous) infection and determination of R. equi burdens in spleen and liver. Here, we investigated the murine lung for experimental infection studies with R. equi. Using a 10(7)CFU intranasal challenge in BALB/c mice, virulent R. equi consistently survived in quantifiable numbers up to 10 days in the lun...
Structural and biochemical insights into the V/I505T mutation found in the EIAV gp45 vaccine strain.
Retrovirology    March 21, 2014   Volume 11 26 doi: 10.1186/1742-4690-11-26
Du J, Wang X, Ma J, Wang J, Qin Y, Zhu C, Liu F, Shao Y, Zhou J, Qiao W, Liu X.The equine infectious anemia virus (EIAV) is a lentivirus of the Retrovirus family, which causes persistent infection in horses often characterized by recurrent episodes of high fever. It has a similar morphology and life cycle to the human immunodeficiency virus (HIV). Its transmembrane glycoprotein, gp45 (analogous to gp41 in HIV), mediates membrane fusion during the infection. However, the post-fusion conformation of EIAV gp45 has not yet been determined. EIAV is the first member of the lentiviruses for which an effective vaccine has been successfully developed. The attenuated vaccine strai...
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health.
Emerging infectious diseases    February 28, 2014   Volume 20, Issue 3 372-379 doi: 10.3201/eid2003.131159
Middleton D, Pallister J, Klein R, Feng YR, Haining J, Arkinstall R, Frazer L, Huang JA, Edwards N, Wareing M, Elhay M, Hashmi Z, Bingham J, Yamada M....In recent years, the emergence of several highly pathogenic zoonotic diseases in humans has led to a renewed emphasis on the interconnectedness of human, animal, and environmental health, otherwise known as One Health. For example, Hendra virus (HeV), a zoonotic paramyxovirus, was discovered in 1994, and since then, infections have occurred in 7 humans, each of whom had a strong epidemiologic link to similarly affected horses. As a consequence of these outbreaks, eradication of bat populations was discussed, despite their crucial environmental roles in pollination and reduction of the insect p...
Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus.
Journal of virological methods    February 5, 2014   Volume 200 22-28 doi: 10.1016/j.jviromet.2014.01.010
McNabb L, Barr J, Crameri G, Juzva S, Riddell S, Colling A, Boyd V, Broder C, Wang LF, Lunt R.Hendra and Nipah viruses (HeV and NiV) are closely related zoonotic pathogens of the Paramyxoviridae family. Both viruses belong to the Henipavirus genus and cause fatal disease in animals and humans, though only HeV is endemic in Australia. In general and due to the acute nature of the disease, agent detection by PCR and virus isolation are the primary tools for diagnostic investigations. Assays for the detection of antibodies against HeV are fit more readily for the purpose of surveillance testing in disease epidemiology and to meet certification requirements in the international movement of...
Long-term methods and effects of remotely treating wildlife with immunocontraception.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians    January 21, 2014   Volume 44, Issue 4 Suppl S138-S140 doi: 10.1638/1042-7260-44.4S.S138
Naugle R, Grams K.The development of sophisticated delivery equipment, as well as safer and more effective drugs, has made remote delivery of animal drugs a standard and readily available tool for wildlife professionals, veterinarians, ranchers, and animal control officers. In the 1980s, researchers began treating a wide variety of wildlife with injectable porcine zona pellucida immunocontraceptive vaccines. Remote delivery of immunocontraceptives has been proven effective at the individual and population level for wild horses and urban deer. However, it took only a short time at each study site to understand t...
Expression of the hemagglutinin HA1 subunit of the equine influenza virus using a baculovirus expression system.
Revista Argentina de microbiologia    January 10, 2014   Volume 45, Issue 4 222-228 doi: 10.1016/S0325-7541(13)70028-2
Sguazza GH, Fuentealba NA, Tizzano MA, Galosi CM, Pecoraro MR.Equine influenza virus is a leading cause of respiratory disease in horses worldwide. Disease prevention is by vaccination with inactivated whole virus vaccines. Most current influenza vaccines are generated in embryonated hens' eggs. Virions are harvested from allantoic fluid and chemically inactivated. Although this system has served well over the years, the use of eggs as the substrate for vaccine production has several well-recognized disadvantages (cost, egg supply, waste disposal and yield in eggs). The aim of this study was to evaluate a baculovirus system as a potential method for prod...
Development of a surveillance scheme for equine influenza in the UK and characterisation of viruses isolated in Europe, Dubai and the USA from 2010-2012.
Veterinary microbiology    December 21, 2013   Volume 169, Issue 3-4 113-127 doi: 10.1016/j.vetmic.2013.11.039
Woodward AL, Rash AS, Blinman D, Bowman S, Chambers TM, Daly JM, Damiani A, Joseph S, Lewis N, McCauley JW, Medcalf L, Mumford J, Newton JR, Tiwari A....Equine influenza viruses are a major cause of respiratory disease in horses worldwide and undergo antigenic drift. Several outbreaks of equine influenza occurred worldwide during 2010-2012, including in vaccinated animals, highlighting the importance of surveillance and virus characterisation. Virus isolates were characterised from more than 20 outbreaks over a 3-year period, including strains from the UK, Dubai, Germany and the USA. The haemagglutinin-1 (HA1) sequence of all isolates was determined and compared with OIE-recommended vaccine strains. Viruses from Florida clades 1 and 2 showed c...
Assessment of the safety and immunogenicity of Rhodococcus equi-secreted proteins combined with either a liquid nanoparticle (IMS 3012) or a polymeric (PET GEL A) water-based adjuvant in adult horses and foals–identification of promising new candidate antigens.
Veterinary immunology and immunopathology    December 17, 2013   Volume 157, Issue 3-4 164-174 doi: 10.1016/j.vetimm.2013.12.003
Cauchard S, Bertrand F, Barrier-Battut I, Jacquet S, Laurentie M, Barbey C, Laugier C, Deville S, Cauchard J.Rhodococcus equi is the most common infectious cause of mortality in foals between 1 and 6 months of age. Because of an increase in the number of antibiotic-resistant strains, the optimization of a prophylactic strategy is a key factor in the comprehensive management of R. equi pneumonia. The objectives of this study were to assess the safety and immunogenicity of R. equi-secreted proteins (ReSP) co-administered with either the nanoparticular adjuvant Montanide™ IMS 3012 VG, or a new polymeric adjuvant Montanide™ PET GEL A, and to further investigate the most immunogenic proteins for subse...
Experimental infection with equine herpesvirus type 1 (EHV-1) induces chorioretinal lesions.
Veterinary research    December 5, 2013   Volume 44, Issue 1 118 doi: 10.1186/1297-9716-44-118
Hussey GS, Goehring LS, Lunn DP, Hussey SB, Huang T, Osterrieder N, Powell C, Hand J, Holz C, Slater J.Equine herpesvirus myeloencephalitis (EHM) remains one of the most devastating manifestations of equine herpesvirus type 1 (EHV-1) infection but our understanding of its pathogenesis remains rudimentary, partly because of a lack of adequate experimental models. EHV-1 infection of the ocular vasculature may offer an alternative model as EHV-1-induced chorioretinopathy appears to occur in a significant number of horses, and the pathogenesis of EHM and ocular EHV-1 may be similar. To investigate the potential of ocular EHV-1 as a model for EHM, and to determine the frequency of ocular EHV-1, our ...
Novel vaccination approaches against equine alphavirus encephalitides.
Vaccine    December 2, 2013   Volume 32, Issue 3 311-319 doi: 10.1016/j.vaccine.2013.11.071
Carossino M, Thiry E, de la Grandière A, Barrandeguy ME.The current production of inactivated vaccines for the prevention of equine alphavirus encephalitides caused by Eastern, Western and Venezuelan Equine Encephalitis viruses (EEEV, WEEV, VEEV) involves the manipulation of large quantities of infectious viral particles under biosafety level 3 containment laboratories with the potential risk of transmission to the operators. Moreover, these vaccines are not capable of inducing a long-lasting immunity. Modified live vaccines, which were also attempted, maintain residual virulence and neurotropism, causing disease in both horses and humans. Therefor...
Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.
Viruses    December 2, 2013   Volume 5, Issue 12 2963-2976 doi: 10.3390/v5122963
Craigo JK, Montelaro RC.Equine infectious anemia (EIA), identified in 1843 [1] as an infectious disease of horses and as a viral infection in 1904, remains a concern in veterinary medicine today. Equine infectious anemia virus (EIAV) has served as an animal model of HIV-1/AIDS research since the original identification of HIV. Similar to other lentiviruses, EIAV has a high propensity for genomic sequence and antigenic variation, principally in its envelope (Env) proteins. However, EIAV possesses a unique and dynamic disease presentation that has facilitated comprehensive analyses of the interactions between the evolv...
The evaluation of a nucleoprotein ELISA for the detection of equine influenza antibodies and the differentiation of infected from vaccinated horses (DIVA).
Influenza and other respiratory viruses    November 28, 2013   Volume 7 Suppl 4, Issue Suppl 4 73-80 doi: 10.1111/irv.12195
Galvin P, Gildea S, Arkins S, Walsh C, Cullinane A.Antibodies against equine influenza virus (EIV) are traditionally quantified by haemagglutination inhibition (HI) or single radial haemolysis (SRH). Objective: To evaluate an ELISA for the detection of antibodies against influenza nucleoprotein in the diagnosis and surveillance of equine influenza (EI). Methods: The ELISA was compared with the SRH and HI tests. Serial serum samples from 203 naturally and 14 experimentally infected horses, from 60 weanlings following primary vaccination with five different vaccines (two whole inactivated vaccines, two ISCOM-based subunit vaccines and a recombin...
Management of animal botulism outbreaks: from clinical suspicion to practical countermeasures to prevent or minimize outbreaks.
Biosecurity and bioterrorism : biodefense strategy, practice, and science    November 6, 2013   Volume 11 Suppl 1 S191-S199 doi: 10.1089/bsp.2012.0089
Anniballi F, Fiore A, Löfström C, Skarin H, Auricchio B, Woudstra C, Bano L, Segerman B, Koene M, Båverud V, Hansen T, Fach P, Tevell Aberg A....Botulism is a severe neuroparalytic disease that affects humans, all warm-blooded animals, and some fishes. The disease is caused by exposure to toxins produced by Clostridium botulinum and other botulinum toxin-producing clostridia. Botulism in animals represents a severe environmental and economic concern because of its high mortality rate. Moreover, meat or other products from affected animals entering the food chain may result in a public health problem. To this end, early diagnosis is crucial to define and apply appropriate veterinary public health measures. Clinical diagnosis is based on...
Influenza vaccine strains: licensing perspectives.
Equine veterinary journal    October 15, 2013   Volume 45, Issue 6 772-773 doi: 10.1111/evj.12155
Woodland RM.No abstract available
Equine influenza: antigenic drift and implications for vaccines.
Equine veterinary journal    October 15, 2013   Volume 45, Issue 6 768-769 doi: 10.1111/evj.12148
Elton D, Cullinane A.No abstract available
1 10 11 12 13 14 34